Slovakia Pharma companies in Slovakia are managing to circumvent the problems inherent in the size of the local market by focusing on the country’s advantages in market access and regional leadership, as well as through joining together with affiliates in neighboring Czech Republic. “Slovakia is a developed and established EUR 1.25…
Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…
Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…
France Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this field, with a number of companies, institutes and hospitals pioneering new forms of treatment and adapting policy to fit the…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it a compelling choice. “Switzerland was actually the obvious choice for kick-starting our international operations because the local ecosystem is so…
Czech Republic One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the regional leaders in pharmaceuticals, healthcare and life sciences. In the Czech Republic we have the right balance between sophisticated…
Czech Republic Entrepreneurially-minded individuals, together with academic institutions with their fingers on the pulses of the latest trends, are propelling Czech pharma companies to great success and cementing the Czech Republic at the forefront of healthcare innovation in Central Europe. [Czech know-how should not] be compared with the stereotype of Eastern…
Switzerland’s especially fine reputation for research impact and innovation generation is attracting a host of MNCs to base their European headquarters in the mountain nation and spend big on world-leading cutting-edge R&D. “Switzerland represents an extremely fertile ground for scientific findings” Walter Steinlin, CTI According to the yearly European and…
Hungary One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If we take the case of pathology as a small specialty among other important specialties in Hungary, we are only 250…
Hungary Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have one of the most complex and comprehensive regulatory frameworks in Europe, which aims to cover all medical and medicinal needs…
Hungary Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence and support of Italy-based Kedrion Biopharma has the company been able to transform into the powerhouse that is today. …
See our Cookie Privacy Policy Here
